Biofrontera Inc.

Biofrontera Inc. (BFRI) priced its initial public offering on Nov 1, 2021 at $5.00 per share, raising $18M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $58M. Roth Capital was lead-left underwriter, joined by Benchmark. McGuireWoods advised the company and Schiff Hardin advised the underwriters.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing treatments for dermatological conditions caused by sun exposure. Its principal licensed product, Ameluz, is used with a lamp for photodynamic therapy of actinic keratosis, and it also markets a topical antibiotic for impetigo.

Status

IPO

Ticker

BFRI

Exchange

Nasdaq Capital Market

Priced

Nov 1, 2021

IPO price

$5.00

Raised

$18M

Market cap at IPO price

$58M

First filed

Jul 6, 2021

Underwriters

Roth Capital and Benchmark

Company counsel

McGuireWoods

Underwriters' counsel

Schiff Hardin

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.